Keywords: new, study, shows, benefit, reopro, eli, lilly
New study shows no benefit for ReoPro
Article | 20 October 2000
Eli Lilly and Johnson & Johnson's ReoPro (abciximab) was less effectivethan stenting alone in reducing major adverse cardiac events following myocardial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
